Shots:

• The approval is based on P-III ETHOS study assessing of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) vs dual therapies [Bevespi Aerosphere (glycopyrronium/formoterol fumarate) and PT009 (budesonide/formoterol fumarate)] with mod. to sev. COPD and a history of exacerbation(s) in the previous year
• The P-III ETHOS study demonstrated a reduction in the rate of moderate or severe exacerbations. Additionally- the P-III KRONOS study also support the approval of the therapy
• Breztri Aerosphere is an approved therapy in Japan and China for patients with COPD and is under regulatory review in the EU. As per the agreement to acquire Pearl Therapeutics- AstraZeneca paid $150M as a milestone on US approval of the therapy for COPD

  Ref: AstraZeneca | Image: AstraZeneca